Compare CLIR & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLIR | FEMY |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.4M | 35.4M |
| IPO Year | 2012 | 2021 |
| Metric | CLIR | FEMY |
|---|---|---|
| Price | $0.72 | $0.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.00 | ★ $6.83 |
| AVG Volume (30 Days) | 147.0K | ★ 1.3M |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,153,000.00 | $2,061,502.00 |
| Revenue This Year | $13.13 | $64.02 |
| Revenue Next Year | $143.88 | $147.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 63.53 |
| 52 Week Low | $0.46 | $0.31 |
| 52 Week High | $1.53 | $1.80 |
| Indicator | CLIR | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 45.02 |
| Support Level | $0.63 | $0.60 |
| Resistance Level | $0.81 | $0.73 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 59.00 | 45.12 |
ClearSign Technologies Corp is engaged in providing solutions to some of the pressing productivity, energy efficiency, and pollution problems affecting the energy, oil, and gas production, boiler, and processing industries. It believes that its patented ClearSign Core technology can enhance the performance of combustion systems in a broad range of markets, including the energy (upstream oil production and downstream refining), institutional, commercial, and industrial boiler, chemical, and petrochemical industries. The company offers products that include process burners, boiler burners, flares, and ClearSign Eye.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.